Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 21, 2021; 27(15): 1595-1615
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Figure 7 Abelson interactor 1 splice isoform-L interacts with WAVE2, phosphorylated or non-phosphorylated Abelson interactor 1-p65, and NAP-1 in SW480 cells.
A and B: Abelson interactor 1 splice isoform-L (ABI1-SiL) overexpression does not change the mRNA (A) or protein (B) expression of WAVE2; C and D: Co-immunoprecipitates (IP) were subjected to Western blot using the indicated antibodies. Bidirectional co-IP and Western blot analysis show that both ABI1-p65 and ABI1-SiL bind to WAVE2 in SW480-V (C) and SW480-ABI1-SiL6 cells (D); E: ABI1-SiL interacts with phosphorylated and non-phosphorylated ABI1-p65 in SW480 cells (arrows). ABI1-SiL does not bind to NAP-1, but ABI1-p65 does. ABI1-SiL: Abelson interactor 1 splice isoform-L; ABI1: Abelson interactor 1; GFP: Green fluorescence protein; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
- Citation: Li K, Peng YF, Guo JZ, Li M, Zhang Y, Chen JY, Lin TR, Yu X, Yu WD. Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1. World J Gastroenterol 2021; 27(15): 1595-1615
- URL: https://www.wjgnet.com/1007-9327/full/v27/i15/1595.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i15.1595